\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Digital, Industry & Space AI ContinentThe European Commission’s Artificial Intelligence (AI) Office has launched a targeted stakeholders consultation process on the future guidelines on the AI system definition and the implementation of AI practices that pose unacceptable risks under the AI Act.
The guidelines will help national competent authorities as well as providers and deployers in complying with the AI Act’s rules on such AI practices ahead of the application of the relevant provisions on 2 February 2025.
The AI Office invites stakeholders, including AI systems providers, businesses, national authorities, academia, research institutions and civil society to submit their input. The contributions received will feed into the Commission's guidelines on the definition of AI system and prohibited AI practices under the AI Act, to be published in early 2025.
The legal concepts regarding the AI system definition and prohibited AI practices are established in the AI Act. This consultation seeks additional practical examples from stakeholders to feed into the guidelines and provide further clarity on practical aspects and use cases.
The consultation is open for stakeholder input until 11 December 2024.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Horizon Europe Digital Europe
Building on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
